Roadmap To Successful Drug Therapy Partnerships

In a featured video presentation, Erik Jerks, Director at Eurofins Bioanalytical Services, shares expert insights into strategies for bioanalytical method development and validation, particularly for complex biologics. He emphasizes Eurofins’ depth of experience and technical capabilities in developing robust, customized bioanalytical assays to meet the evolving needs of clients working with biologic therapeutics.

Jerks discusses three case studies that spotlight specific challenges and solutions in assay development for bispecific multitarget antibodies and adeno-associated virus (AAV)-based gene therapy products. These examples highlight how Eurofins tailors its approach to address the unique analytical hurdles posed by complex modalities. By integrating evolving technologies, such as automated instrumentation platforms, Eurofins is able to improve efficiency, precision, and reproducibility in assay performance.

The presentation underscores the growing need for method flexibility, sensitivity, and scalability as biologics become more sophisticated and personalized. Jerks points out that staying ahead of industry demands requires not only technical proficiency but also strategic thinking in assay planning and validation. Automation and technology integration play a key role in minimizing variability and maximizing throughput, essential factors in supporting regulatory submissions and clinical development timelines.

Ultimately, Eurofins’ collaborative approach, combined with its robust technological infrastructure, allows for the development of high-quality bioanalytical solutions that align with diverse client goals and regulatory standards. This positions Eurofins as a trusted partner in advancing complex biologic and gene therapy programs through every stage of the development pipeline.